Please input keywords
top
YH003
2021.01.12

Drug : YH003(CD40)

Progress : Phase I/II clinical trial

Indication : Phase I for solid tumor; Phase II for melanoma, and pancreatic cancer


Country/Region : Australia

Study Title : A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in combination with Toripalimab (anti-PD-1 mAb) in Subjects with Advanced Solid Tumors

Link to Trial : https://clinicaltrials.gov/ct2/show/NCT04481009